Cytosolic beta-glucosidase, also known as cytosolic beta-glucosidase-like protein 1, is a
beta-glucosidase (
EC3.2.1.21)
enzyme that in humans is encoded by the GBA3gene.[3][4]
Function
Cytosolic beta-glucosidase is a predominantly liver enzyme that efficiently hydrolyzes beta-D-glucoside and beta-D-galactoside, but not any known physiologic
beta-glycoside, suggesting that it may be involved in detoxification of plant glycosides.[4] GBA3 also has significant neutral
glycosylceramidase activity (
EC3.2.1.62), suggesting that it may be involved in a non-
lysosomal catabolic pathway of
glucosylceramide metabolism.[5]
Beutler E, Beutler L, West C (2004). "Mutations in the gene encoding cytosolic beta-glucosidase in Gaucher disease". J. Lab. Clin. Med. 144 (2): 65–8.
doi:
10.1016/j.lab.2004.03.013.
PMID15322500.
Yahata K, Mori K, Arai H, et al. (2000). "Molecular cloning and expression of a novel klotho-related protein". J. Mol. Med. 78 (7): 389–94.
doi:
10.1007/s001090000131.
PMID11043382.
S2CID20851692.
Tribolo S, Berrin JG, Kroon PA, et al. (2007). "The crystal structure of human cytosolic beta-glucosidase unravels the substrate aglycone specificity of a family 1 glycoside hydrolase". J. Mol. Biol. 370 (5): 964–75.
doi:
10.1016/j.jmb.2007.05.034.
PMID17555766.
Noguchi J, Hayashi Y, Baba Y, et al. (2008). "Crystal structure of the covalent intermediate of human cytosolic beta-glucosidase". Biochem. Biophys. Res. Commun. 374 (3): 549–52.
doi:
10.1016/j.bbrc.2008.07.089.
PMID18662675.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56.
doi:
10.1016/S0378-1119(97)00411-3.
PMID9373149.
Wolk T, Schreiber M (2006). "N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization". Med. Microbiol. Immunol. 195 (3): 165–72.
doi:
10.1007/s00430-006-0016-z.
PMID16547752.
S2CID31347157.
Dekker N, Voorn-Brouwer T, Verhoek M, et al. (2010). "The cytosolic beta-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation". Blood Cells Mol. Dis. 46 (1): 19–26.
doi:
10.1016/j.bcmd.2010.07.009.
PMID20728381.
Németh K, Plumb GW, Berrin JG, et al. (2003). "Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans". Eur J Nutr. 42 (1): 29–42.
doi:
10.1007/s00394-003-0397-3.
PMID12594539.
S2CID20146480.
Cytosolic beta-glucosidase, also known as cytosolic beta-glucosidase-like protein 1, is a
beta-glucosidase (
EC3.2.1.21)
enzyme that in humans is encoded by the GBA3gene.[3][4]
Function
Cytosolic beta-glucosidase is a predominantly liver enzyme that efficiently hydrolyzes beta-D-glucoside and beta-D-galactoside, but not any known physiologic
beta-glycoside, suggesting that it may be involved in detoxification of plant glycosides.[4] GBA3 also has significant neutral
glycosylceramidase activity (
EC3.2.1.62), suggesting that it may be involved in a non-
lysosomal catabolic pathway of
glucosylceramide metabolism.[5]
Beutler E, Beutler L, West C (2004). "Mutations in the gene encoding cytosolic beta-glucosidase in Gaucher disease". J. Lab. Clin. Med. 144 (2): 65–8.
doi:
10.1016/j.lab.2004.03.013.
PMID15322500.
Yahata K, Mori K, Arai H, et al. (2000). "Molecular cloning and expression of a novel klotho-related protein". J. Mol. Med. 78 (7): 389–94.
doi:
10.1007/s001090000131.
PMID11043382.
S2CID20851692.
Tribolo S, Berrin JG, Kroon PA, et al. (2007). "The crystal structure of human cytosolic beta-glucosidase unravels the substrate aglycone specificity of a family 1 glycoside hydrolase". J. Mol. Biol. 370 (5): 964–75.
doi:
10.1016/j.jmb.2007.05.034.
PMID17555766.
Noguchi J, Hayashi Y, Baba Y, et al. (2008). "Crystal structure of the covalent intermediate of human cytosolic beta-glucosidase". Biochem. Biophys. Res. Commun. 374 (3): 549–52.
doi:
10.1016/j.bbrc.2008.07.089.
PMID18662675.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56.
doi:
10.1016/S0378-1119(97)00411-3.
PMID9373149.
Wolk T, Schreiber M (2006). "N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization". Med. Microbiol. Immunol. 195 (3): 165–72.
doi:
10.1007/s00430-006-0016-z.
PMID16547752.
S2CID31347157.
Dekker N, Voorn-Brouwer T, Verhoek M, et al. (2010). "The cytosolic beta-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation". Blood Cells Mol. Dis. 46 (1): 19–26.
doi:
10.1016/j.bcmd.2010.07.009.
PMID20728381.
Németh K, Plumb GW, Berrin JG, et al. (2003). "Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans". Eur J Nutr. 42 (1): 29–42.
doi:
10.1007/s00394-003-0397-3.
PMID12594539.
S2CID20146480.